Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Collegium Pharmaceutical Inc

Healthcare US COLL

36.61USD
-0.66(1.77%)

Last update at 2026-03-10T20:18:00Z

Day Range

36.4537.76
LowHigh

52 Week Range

20.8340.95
LowHigh

Fundamentals

  • Previous Close 37.27
  • Market Cap1117.23M
  • Volume403183
  • P/E Ratio13.61
  • Dividend Yield-%
  • EBITDA343.16M
  • Revenue TTM566.92M
  • Revenue Per Share TTM17.05
  • Gross Profit TTM 345.74M
  • Diluted EPS TTM2.51

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -28.84700M -3.37400M 27.58M -22.72200M -39.12800M
Minority interest - - - - -
Net income -25.00200M 71.52M 26.75M -8.14800M -39.12800M
Selling general administrative 172.19M 118.96M 113.83M 116.45M 126.76M
Selling and marketing expenses - - - 116.45M 126.76M
Gross profit 209.49M 150.62M 179.84M 103.04M 114.74M
Reconciled depreciation 138.94M 68.92M 61.55M 15.48M 110.91M
Ebit -104.57300M -46.69900M -5.08600M -23.74800M -20.68500M
Ebitda 34.37M 22.22M 56.46M -21.81300M -18.99800M
Depreciation and amortization 138.94M 68.92M 61.55M 1.94M 1.69M
Non operating income net other 1.05M 0.01M 0.23M 1.94M 1.69M
Operating income -104.57300M -46.69900M -5.08600M -23.74800M -20.68500M
Other operating expenses 430.61M 254.66M 253.78M 320.45M 301.10M
Interest expense 63.21M 21.01M 28.88M 0.91M 20.13M
Tax provision -3.84500M -74.89100M 0.83M - -
Interest income 1.05M 0.01M 0.23M 1.94M 1.69M
Net interest income -62.16600M -21.00200M -28.65000M 1.03M -18.44300M
Extraordinary items - - - - -
Non recurring - 4.58M - - -
Other items - - - - -
Income tax expense -3.84500M -74.89100M 0.83M -14.57400M -110.90800M
Total revenue 463.93M 276.87M 310.02M 296.70M 280.41M
Total operating expenses 176.17M 128.41M 123.60M 126.79M 135.42M
Cost of revenue 254.44M 126.25M 130.18M 193.66M 165.68M
Total other income expense net 75.73M 43.33M 32.67M 1.03M -18.44300M
Discontinued operations - - - - -
Net income from continuing ops -25.00200M 71.52M 26.75M -22.72200M -39.12800M
Net income applicable to common shares -25.00200M 71.52M 26.75M -22.72200M -39.12800M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 1143.31M 1174.13M 692.08M 643.84M 306.30M
Intangible assets 421.71M 567.47M 268.72M 335.90M 29.50M
Earning assets - - - - -
Other current assets 0.09M 16.68M 0.03M 0.06M 0.14M
Total liab 947.88M 979.29M 489.15M 457.81M 218.87M
Total stockholder equity 195.43M 194.84M 202.93M 186.03M 87.43M
Deferred long term liab - - - - -
Other current liab 264.90M 66.88M 147.83M 108.33M 153.06M
Common stock 0.04M 0.04M 0.04M 0.04M 0.03M
Capital stock 0.04M 0.04M 0.04M 0.04M 0.03M
Retained earnings -233.18900M -281.34400M -256.34200M -333.14700M -359.89900M
Other liab - - - - -
Good will 133.86M 133.69M - - -
Other assets - 19.33M 942.74M 0.01M 0.18M
Cash 238.95M 173.69M 186.43M 174.12M 170.02M
Cash and equivalents - - - - -
Total current liabilities 457.92M 270.11M 230.40M 191.23M 197.28M
Current deferred revenue - - - - -
Net debt 435.34M 699.10M 72.32M 92.47M -148.42500M
Short term debt 184.32M 163.61M 49.17M 48.23M 4.49M
Short long term debt 183.33M 162.50M 48.35M 47.49M 3.83M
Short long term debt total 674.28M 872.79M 258.75M 266.58M 21.59M
Other stockholder equity 428.57M 476.15M 459.23M 519.14M 447.30M
Property plant equipment - 19.52M 19.49M 18.99M 20.90M
Total current assets 537.60M 419.99M 315.54M 277.89M 255.72M
Long term investments - - - - -
Net tangible assets - -506.32100M -65.79500M -149.87300M 57.93M
Short term investments 71.60M - - - -
Net receivables 179.53M 183.12M 105.84M 83.32M 72.95M
Long term debt 483.84M 538.45M 201.63M 209.59M 7.67M
Inventory 32.33M 46.50M 17.39M 15.61M 9.64M
Accounts payable 8.69M 39.62M 33.40M 34.67M 39.73M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.01M - - - -2.28800M
Additional paid in capital - - - - -
Common stock total equity - 0.04M 0.04M 0.04M 0.03M
Preferred stock total equity - - - - -
Retained earnings total equity - -281.34400M -256.34200M -333.14700M -359.89900M
Treasury stock - - -42.86100M - -
Accumulated amortization - - - - -
Non currrent assets other 0.83M 2.65M 2.63M 2.67M 0.18M
Deferred long term asset charges - - - - -
Non current assets total 605.71M 754.14M 376.53M 365.95M 50.58M
Capital lease obligations 7.11M 8.22M 8.77M 9.49M 10.09M
Long term debt total - 538.45M 201.63M 209.59M 7.67M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -573.69100M -1.94400M -373.77200M -6.43800M -24.35400M
Change to liabilities -11.83800M -1.05000M -4.06900M -0.52300M 26.14M
Total cashflows from investing activities -573.69100M -1.94400M -373.77200M -6.43800M -24.35400M
Net borrowings -75.00000M -50.00000M 281.39M 281.39M 10.02M
Total cash from financing activities 436.72M -89.30300M 286.47M 2.04M -117.19700M
Change to operating activities -38.50000M 44.13M -10.43100M 20.92M 126.10M
Net income -25.00200M 71.52M 26.75M -22.72200M -39.12800M
Change in cash -12.73800M 12.31M 6.64M 23.39M 27.84M
Begin period cash flow 188.97M 176.66M 170.02M 146.63M 118.79M
End period cash flow 176.24M 188.97M 176.66M 170.02M 146.63M
Total cash from operating activities 124.23M 103.56M 93.94M 27.78M 169.39M
Issuance of capital stock - - 0.00000M - -
Depreciation 138.94M 68.92M 61.55M 15.48M 110.91M
Other cashflows from investing activities -572.06900M - -368.22600M - -18.87700M
Dividends paid - - - - -
Change to inventory 48.27M -2.29600M -8.27000M -1.82600M 0.22M
Change to account receivables -21.78000M -22.52400M -10.36700M 4.99M -68.23100M
Sale purchase of stock -14.06300M -47.86100M 0.76M 0.82M -0.03000M
Other cashflows from financing activities 513.98M 8.56M 334.72M 1.22M -117.13700M
Change to netincome 14.48M -53.78700M 21.91M 16.53M 33.06M
Capital expenditures 1.62M 1.94M 373.77M 6.44M 24.35M
Change receivables -21.78000M -22.52400M -10.36700M 4.99M -68.23100M
Cash flows other operating 109.12M 39.37M -2.53600M 15.85M 106.43M
Exchange rate changes - - - - -
Cash and cash equivalents changes -12.73800M 12.31M 6.64M 23.39M 27.84M
Change in working capital -12.71300M 13.49M -25.29900M 18.18M 64.55M
Stock based compensation 22.87M 24.25M 21.91M 16.53M 13.78M
Other non cash items 8.52M 3.42M 9.03M 0.31M 19.28M
Free cash flow 122.61M 101.61M -279.83000M 21.34M 145.04M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
COLL
Collegium Pharmaceutical Inc		 -0.66 1.77% 36.61 13.61 5.78 2.06 5.98 2.70 4.97
ZTS
Zoetis Inc		 -1.87 1.53% 120.49 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 0.56 2.23% 25.64 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -2.64 2.02% 128.01 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR		 0.14 0.77% 18.21 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

View All

Profile

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Collegium Pharmaceutical Inc

100 Technology Center Drive, Stoughton, MA, United States, 02072

Key Executives

Name Title Year Born
Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph. Co-Founder & Chairman 1964
Mr. Joseph J. Ciaffoni Pres, CEO & Director 1971
Ms. Colleen Tupper Exec. VP & CFO 1976
Ms. Shirley R. Kuhlmann Exec. VP, Gen. Counsel, Chief Admin. Officer & Sec. 1984
Mr. Scott Dreyer Exec. VP & Chief Commercial Officer 1973
Dr. Richard Malamut M.D. Exec. VP & Chief Medical Officer 1960
Ms. Alex Dasalla Head of Investor Relations NA
Mr. Bart J. Dunn Exec. VP of Strategy & Corp. Devel. NA
Ms. Marlo Manning Head of HR NA
Mr. Scott Sudduth Head of Technical Operations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.